Faron Pharmaceuticals Oy

FARN.L · LSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Market Cap£219,230£233,541£187,977£161,933
- Cash£9,503£6,875£6,990£6,853
+ Debt£12,113£13,111£13,269£3,547
Enterprise Value£221,840£239,777£194,256£158,627
Revenue£0£0£0£0
% Growth
Gross Profit£0£0£0£0
% Margin
EBITDA-£18-£28,371-£27,057-£20,973
% Margin
Net Income-£26-£30,944-£28,730-£21,194
% Margin
EPS Diluted-0-0.34-0.38-0.29
% Growth99.9%10.5%-31%
Operating Cash Flow-£22,971-£23,806-£22,993-£22,218
Capital Expenditures-£226-£123-£385-£474
Free Cash Flow-£23,197-£23,929-£23,378-£22,692
Faron Pharmaceuticals Oy (FARN.L) Financial Statements & Key Stats | AlphaPilot